Nasdaq · CIK 0000842023
TECH BIO-TECHNE Corp
Insider trading from SEC Form 4. Last filing 12 d ago. Close $72.46 on Oct 9, 2026, +68% from the 52-week low and -0% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
13
with a Form 4 at this company
Price and insider trades, last year
TECHOct 9, 2026 · close 72.46
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BIO-TECHNE Corp, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | Robert Baumgartner V director sell | $958k 17,040 shares | -28% | +22% from low-29% from high | |
| 42Moderate | Roeland Nusse director sell | $960k 17,040 shares | -28% | +22% from low-29% from high | |
| 18Weak | Amy E. Herr director sell | $64k 1,280 shares | -39% | +7% from low-38% from high | |
| 20Weak | Amy E. Herr director sell | $123k 1,860 shares | -48% | - | |
| 45Moderate | Kim Kelderman Chief Executive Officer sell | $1.0M 13,392 shares | -26% | - |
Congressional trades
14 trades in TECH disclosed by members of Congress under the STOCK Act. All congressional trades.
- April McClain DelaneyHouse · D-MD · last May 6, 20265 bought
6 sold - Robert P. Bresnahan, Jr.House · R-PA · last May 8, 20251 bought
1 sold - Julie JohnsonHouse · D-TX · last May 14, 20250 bought
1 sold
| Member | Trade | Asset | Reported range | Trade / filing date | Source |
|---|---|---|---|---|---|
April McClain Delaney House · D-MD | Sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Apr 8 / May 6 28 days after the trade | Clerk |
April McClain Delaney House · D-MD | Partial sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Mar 26 / Apr 6 11 days after the trade | Clerk |
April McClain Delaney House · D-MD | Partial sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Feb 24 / Mar 10 14 days after the trade | Clerk |
April McClain Delaney House · D-MD | Partial sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Jan 28 / Feb 2 5 days after the trade | Clerk |
April McClain Delaney House · D-MD | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Dec 2, 2025 / Jan 5 34 days after the trade | Clerk |
April McClain Delaney House · D-MD | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Dec 5, 2025 / Jan 5 31 days after the trade | Clerk |
April McClain Delaney House · D-MD | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Oct 22, 2025 / Nov 4, 2025 13 days after the trade | Clerk |
April McClain Delaney House · D-MD | Partial sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Aug 1, 2025 / Sep 2, 2025 32 days after the trade | Clerk |
April McClain Delaney House · D-MD | Partial sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | May 26, 2025 / Jul 2, 2025 37 days after the trade | Clerk |
Julie Johnson House · D-TX | Sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Apr 1, 2025 / May 14, 2025 43 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Sale | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Apr 8, 2025 / May 8, 2025 30 days after the trade | Clerk |
April McClain Delaney House · D-MD | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Apr 9, 2025 / May 2, 2025 23 days after the trade | Clerk |
April McClain Delaney House · D-MD | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Apr 29, 2025 / May 2, 2025 3 days after the trade | Clerk |
Robert P. Bresnahan, Jr. House · R-PA | Purchase | TECH Bio-Techne Corp - Common Stock | $1,001 to $15k | Feb 25, 2025 / Mar 27, 2025 30 days after the trade | Clerk |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 28, 2026 | John L Higgins director | MOption exercise Common Stock | +15,940 | $0.00 | $0 | 82,816 | 12 d ago |
| Sep 28, 2026 | John L Higgins director | FTax withholding Common Stock | -5,562 | $72.51 | $403k | 77,254 | 12 d ago |
| Sep 28, 2026 | John L Higgins director | MOption exercise Stock Options (Right to Buy)derivative | -15,940 | $0.00 | $0 | 0 | 12 d ago |
| Sep 22, 2026 | Robert Baumgartner V director | MOption exercise Common Stock | +15,940 | $0.00 | $0 | 62,443 | 18 d ago |
| Sep 22, 2026 | Robert Baumgartner V director | FTax withholding Common Stock | -5,559 | $72.55 | $403k | 56,884 | 18 d ago |
| Sep 22, 2026 | Robert Baumgartner V director | MOption exercise Stock Options (Right to Buy)derivative | -15,940 | $0.00 | $0 | 0 | 18 d ago |
| Aug 25, 2025 | Roeland Nusse director | MOption exercise Common Stock | +17,040 | $21.84 | $372k | 61,599 | Aug 27, 2025 |
| Aug 25, 2025 | Robert Baumgartner V director | MOption exercise Common Stock | +17,040 | $21.84 | $372k | 61,903 | Aug 27, 2025 |
| Aug 25, 2025 | Robert Baumgartner V director | SOpen-market sale Common Stock | -17,040 | $56.21 | $958k | 44,863 | Aug 27, 2025 |
| Aug 25, 2025 | Roeland Nusse director | SOpen-market sale Common Stock | -17,040 | $56.36 | $960k | 44,559 | Aug 27, 2025 |
| Aug 25, 2025 | Robert Baumgartner V director | MOption exercise Stock Options (Right to Buy)derivative | -17,040 | $0.00 | $0 | 0 | Aug 27, 2025 |
| Aug 25, 2025 | Roeland Nusse director | MOption exercise Stock Options (Right to Buy)derivative | -17,040 | $0.00 | $0 | 0 | Aug 27, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | MOption exercise Common Stock | +2,637 | $0.00 | $0 | 5,615 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Common Stock | +8,543 | $0.00 | $0 | 55,273 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | MOption exercise Common Stock | +4,010 | $0.00 | $0 | 131,809 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | MOption exercise Common Stock | +1,718 | $0.00 | $0 | 4,912 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Common Stock | +2,623 | $0.00 | $0 | 15,915 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | FTax withholding Common Stock | -4,305 | $53.60 | $231k | 50,968 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | MOption exercise Common Stockindirect: By significant other | +279 | $0.00 | $0 | 2,255 | Aug 19, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | FTax withholding Common Stock | -880 | $53.60 | $47k | 4,735 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | FTax withholding Common Stock | -1,926 | $53.60 | $103k | 129,883 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | FTax withholding Common Stock | -527 | $53.60 | $28k | 4,385 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | FTax withholding Common Stock | -803 | $53.60 | $43k | 15,112 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | FTax withholding Common Stockindirect: By significant other | -101 | $53.60 | $5,414 | 2,154 | Aug 19, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | MOption exercise Restricted Stock Unitsderivative | -2,637 | $0.00 | $0 | 5,275 | Aug 19, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | AGrant or award Performance Restricted Stock Unitsderivative | +19,243 | $0.00 | $0 | 19,243 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | MOption exercise Restricted Stock Unitsderivative | -50 | $0.00 | $0 | 49 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Restricted Stock Unitsderivative | -2,623 | $0.00 | $0 | 5,246 | Aug 19, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | AGrant or award Restricted Stock Unitsderivative | +9,622 | $0.00 | $0 | 9,622 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | AGrant or award Performance Restricted Stock Unitsderivative | +19,355 | $0.00 | $0 | 19,355 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | MOption exercise Restricted Stock Unitsderivativeindirect: By significant other | -119 | $0.00 | $0 | 118 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | MOption exercise Restricted Stock Unitsderivative | -4,010 | $0.00 | $0 | 8,021 | Aug 19, 2025 |
| Aug 15, 2025 | Matthew McManus President - Diag & Spatial Bio | AGrant or award Stock Option (Right to Buy)derivative | +24,614 | $0.00 | $0 | 24,614 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | AGrant or award Restricted Stock Unitsderivative | +9,678 | $0.00 | $0 | 9,678 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | MOption exercise Restricted Stock Unitsderivativeindirect: By significant other | -160 | $0.00 | $0 | 320 | Aug 19, 2025 |
| Aug 15, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | AGrant or award Stock Options (Right to Buy)derivative | +24,758 | $0.00 | $0 | 24,758 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | MOption exercise Restricted Stock Unitsderivative | -1,668 | $0.00 | $0 | 3,338 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Restricted Stock Unitsderivative | -8,543 | $0.00 | $0 | 17,087 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | AGrant or award Restricted Stock Unitsderivativeindirect: By significant other | +932 | $0.00 | $0 | 932 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | AGrant or award Performance Restricted Stock Unitsderivative | +29,420 | $0.00 | $0 | 29,420 | Aug 19, 2025 |
| Aug 15, 2025 | Amy E. Herr director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By significant other | +2,735 | $0.00 | $0 | 2,735 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | AGrant or award Restricted Stock Unitsderivative | +14,710 | $0.00 | $0 | 14,710 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | AGrant or award Performance Restricted Stock Unitsderivative | +13,992 | $0.00 | $0 | 13,992 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | AGrant or award Performance Restricted Stock Unitsderivative | +70,708 | $0.00 | $0 | 70,708 | Aug 19, 2025 |
| Aug 15, 2025 | James Hippel CFO | AGrant or award Stock Options (Right to Buy)derivative | +37,632 | $0.00 | $0 | 37,632 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | AGrant or award Restricted Stock Unitsderivative | +6,996 | $0.00 | $0 | 6,996 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | AGrant or award Restricted Stock Unitsderivative | +35,354 | $0.00 | $0 | 35,354 | Aug 19, 2025 |
| Aug 15, 2025 | Shane Bohnen SVP - General Counsel | AGrant or award Stock Option (Right to Buy)derivative | +17,897 | $0.00 | $0 | 17,897 | Aug 19, 2025 |
| Aug 15, 2025 | Kim Kelderman Chief Executive Officer | AGrant or award Stock Options (Right to Buy)derivative | +90,441 | $0.00 | $0 | 90,441 | Aug 19, 2025 |
| Aug 7, 2025 | John L Higgins director | MOption exercise Common Stock | +5,040 | $21.84 | $110k | 65,236 | Aug 11, 2025 |
| Aug 7, 2025 | John L Higgins director | MOption exercise Stock Option (Right to Buy)derivative | -5,040 | $0.00 | $0 | 0 | Aug 11, 2025 |
| Jul 29, 2025 | James Hippel CFO | MOption exercise Common Stock | +168,620 | $44.33 | $7.5M | 275,230 | Jul 31, 2025 |
| Jul 29, 2025 | James Hippel CFO | FTax withholding Common Stock | -147,431 | $58.55 | $8.6M | 127,799 | Jul 31, 2025 |
| Jul 29, 2025 | James Hippel CFO | MOption exercise Stock Options (Right to Buy)derivative | -168,620 | $0.00 | $0 | 0 | Jul 31, 2025 |
| Jul 22, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Common Stock | +48,176 | $44.33 | $2.1M | 90,379 | Jul 24, 2025 |
| Jul 22, 2025 | Kim Kelderman Chief Executive Officer | FTax withholding Common Stock | -43,649 | $53.12 | $2.3M | 46,730 | Jul 24, 2025 |
| Jul 22, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -48,176 | $0.00 | $0 | 0 | Jul 24, 2025 |
| Jul 15, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Common Stock | +36,132 | $44.33 | $1.6M | 75,136 | Jul 17, 2025 |
| Jul 15, 2025 | Kim Kelderman Chief Executive Officer | FTax withholding Common Stock | -32,933 | $51.42 | $1.7M | 42,203 | Jul 17, 2025 |
| Jul 15, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -36,132 | $0.00 | $0 | 48,176 | Jul 17, 2025 |
| Jun 9, 2025 | Amy E. Herr director | MOption exercise Common Stockindirect: By significant other | +1,280 | $44.33 | $57k | 3,256 | Jun 11, 2025 |
| Jun 9, 2025 | Amy E. Herr director | SOpen-market sale Common Stockindirect: By significant other | -1,280 | $49.77 | $64k | 1,976 | Jun 11, 2025 |
| Jun 9, 2025 | Amy E. Herr director | MOption exercise Stock Option (Right to Buy)derivativeindirect: By significant other | -1,280 | $0.00 | $0 | 0 | Jun 11, 2025 |
| May 1, 2025 | John L Higgins director | MOption exercise Common Stock | +12,000 | $21.84 | $262k | 60,196 | May 5, 2025 |
| May 1, 2025 | John L Higgins director | MOption exercise Stock Options (Right to Buy)derivative | -12,000 | $0.00 | $0 | 5,040 | May 5, 2025 |
| Jul 1, 2019 | Rupert Vessey director | AGrant or award Stock Options (Right to Buy)derivative | +588 | $0.00 | $0 | 588 | Apr 11, 2025 |
| Apr 3, 2025 | Shane Bohnen SVP - General Counsel | MOption exercise Common Stock | +2,260 | $0.00 | $0 | 3,941 | Apr 7, 2025 |
| Apr 3, 2025 | Shane Bohnen SVP - General Counsel | FTax withholding Common Stock | -747 | $54.86 | $41k | 3,194 | Apr 7, 2025 |
| Apr 3, 2025 | Shane Bohnen SVP - General Counsel | MOption exercise Restricted Stock Unitsderivative | -2,260 | $0.00 | $0 | 2,259 | Apr 7, 2025 |
| Feb 14, 2025 | Amy E. Herr director | MOption exercise Common Stockindirect: By significant other | +1,976 | $44.33 | $88k | 3,836 | Feb 18, 2025 |
| Feb 14, 2025 | Amy E. Herr director | SOpen-market sale Common Stockindirect: By significant other | -1,860 | $65.96 | $123k | 1,976 | Feb 18, 2025 |
| Feb 14, 2025 | Amy E. Herr director | MOption exercise Stock Option (Right to Buy)derivativeindirect: By significant other | -1,976 | $0.00 | $0 | 1,280 | Feb 18, 2025 |
| Feb 3, 2025 | Amy E. Herr director | AGrant or award Common Stock | +1,040 | $0.00 | $0 | 1,040 | Feb 7, 2025 |
| Feb 3, 2025 | Amy E. Herr director | AGrant or award Stock Option (Right to Buy)derivative | +2,415 | $0.00 | $0 | 2,415 | Feb 7, 2025 |
| Feb 3, 2025 | Amy E. Herr director | AGrant or award Stock Option (Right to Buy)derivativeindirect: By significant other | +344 | $0.00 | $0 | 344 | Feb 7, 2025 |
| Feb 3, 2025 | Amy E. Herr director | AGrant or award Restricted Stock Unitsderivativeindirect: By significant other | +115 | $0.00 | $0 | 115 | Feb 7, 2025 |
| Feb 1, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Common Stock | +3,320 | $0.00 | $0 | 14,401 | Feb 4, 2025 |
| Feb 1, 2025 | Matthew McManus President - DGS | MOption exercise Common Stock | +4,620 | $0.00 | $0 | 4,620 | Feb 4, 2025 |
| Feb 1, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | FTax withholding Common Stock | -1,109 | $73.55 | $82k | 13,292 | Feb 4, 2025 |
| Feb 1, 2025 | Matthew McManus President - DGS | FTax withholding Common Stock | -1,642 | $73.55 | $121k | 2,978 | Feb 4, 2025 |
| Feb 1, 2025 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Restricted Stock Unitsderivative | -3,320 | $0.00 | $0 | 0 | Feb 4, 2025 |
| Feb 1, 2025 | Matthew McManus President - DGS | MOption exercise Restricted Stock Unitsderivative | -4,620 | $0.00 | $0 | 9,241 | Feb 4, 2025 |
| Jan 27, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Common Stock | +13,392 | $37.70 | $505k | 52,396 | Jan 29, 2025 |
| Jan 27, 2025 | Kim Kelderman Chief Executive Officer | SOpen-market sale Common Stock | -11,731 | $77.19 | $906k | 40,665 | Jan 29, 2025 |
| Jan 27, 2025 | Kim Kelderman Chief Executive Officer | SOpen-market sale Common Stock | -1,661 | $77.95 | $129k | 39,004 | Jan 29, 2025 |
| Jan 27, 2025 | Kim Kelderman Chief Executive Officer | MOption exercise Stock Option (Right to Buy)derivative | -13,392 | $0.00 | $0 | 0 | Jan 29, 2025 |
| Nov 1, 2024 | James Hippel CFO | MOption exercise Common Stock | +13,159 | $0.00 | $0 | 113,085 | Nov 5, 2024 |
| Nov 1, 2024 | Kim Kelderman Chief Executive Officer | FTax withholding Common Stock | -2,430 | $75.31 | $183k | 39,004 | Nov 5, 2024 |
| Nov 1, 2024 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Common Stock | +9,912 | $0.00 | $0 | 14,351 | Nov 5, 2024 |
| Nov 1, 2024 | James Hippel CFO | FTax withholding Common Stock | -6,475 | $75.31 | $488k | 106,610 | Nov 5, 2024 |
| Nov 1, 2024 | William Geist PRESIDENT, PROTEIN SCIENCES | FTax withholding Common Stock | -3,270 | $75.31 | $246k | 11,081 | Nov 5, 2024 |
| Nov 1, 2024 | William Geist PRESIDENT, PROTEIN SCIENCES | MOption exercise Restricted Stock Unitsderivative | -9,912 | $0.00 | $0 | 9,911 | Nov 5, 2024 |
| Nov 1, 2024 | James Hippel CFO | MOption exercise Restricted Stock Unitsderivative | -13,159 | $0.00 | $0 | 13,159 | Nov 5, 2024 |
| Nov 1, 2024 | James Hippel CFO | AGrant or award Restricted Stock Unitsderivative | +34,634 | $0.00 | $0 | 34,634 | Nov 5, 2024 |
| Oct 24, 2024 | Robert Baumgartner V director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 44,863 | Oct 28, 2024 |
| Oct 24, 2024 | Judith Klimovsky V director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 2,142 | Oct 28, 2024 |
| Oct 24, 2024 | Rupert Vessey director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 9,347 | Oct 28, 2024 |
| Oct 24, 2024 | Julie L Bushman director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 7,135 | Oct 28, 2024 |
| Oct 24, 2024 | John L Higgins director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 48,196 | Oct 28, 2024 |
| Oct 24, 2024 | Alpna Seth director | AGrant or award Common Stock | +1,462 | $0.00 | $0 | 13,771 | Oct 28, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Robert Baumgartner Vdirector
- Shane BohnenSVP - General Counsel
- Julie L Bushmandirector
- William GeistPRESIDENT, PROTEIN SCIENCES
- John L Higginsdirector
- Amy E. Herrdirector
- James HippelCFO
- Kim KeldermanChief Executive Officer
- Judith Klimovsky Vdirector
- Matthew McManusPresident - Diag & Spatial Bio
- Roeland Nussedirector
- Alpna Sethdirector
- Rupert Vesseydirector
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.